Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.

@article{Valentine2009LongtermCO,
  title={Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.},
  author={William J. Valentine and Daniel Tucker and A. Jay Palmer and Michael E Minshall and Volker Foos and Cheryl Silberman},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2009},
  volume={12 1},
  pages={1-9}
}
OBJECTIVE To estimate the long-term cost-effectiveness of adding pioglitazone versus placebo to standard treatment in high-risk patients with type 2 diabetes. METHODS The validated CORE Diabetes Model was modified to project long-term clinical and cost outcomes associated with pioglitazone versus placebo, based on results from PROactive. The model retained basic structure and functionality, with interdependent Markov submodels, Monte Carlo simulation and user interface. Adjustments to… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…